Extended Follow-Up May Elucidate How ctDNA Impacts RMC-6236 PDAC Outcomes

Commentary
Video

Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.

CancerNetwork® spoke with Ignacio Garrido-Laguna, MD, PhD, MBA, professor of Oncology and co-leader of the GI Oncology Multidisciplinary Disease Group at the University of Utah Huntsman Cancer Institute, about how circulating tumor DNA (ctDNA) changes in patients who receive daraxonrasib (RMC-6236) may inform further clinical decision-making following a poster presentation of findings from a phase 1 trial (NCT05379985) he gave at the 2025 ASCO Gastrointestinal Cancer Symposium.

Garrido-Laguna began by expressing that the study was a phase 1 trial, and that further research was needed to warrant a definitive answer as to how ctDNA changes may inform clinical decision-making. He further expressed that there were not sufficient data relating to whether patients with certain characteristics, such as those who had a molecular response, had a better response based on ctDNA positivity.

Additionally, he explained that almost all patients on study were reported to have a decrease in ctDNA, with approximately 50% experiencing complete ctDNA eradication. Additionally, many patients who experienced some molecular response reported decreasing ctDNA. Garrido-Laguna then expressed that future follow-up would help clarify how these findings may translate to improved outcomes for patients with stable disease.

Findings from the study revealed a benefit among patients classified as having KRAS G12X mutations vs those identified as having RAS mutations. For patients treated with 300 mg of daraxonrasib, the median progression-free survival (PFS) was 8.8 months (95% CI, 8.5-not evaluable [NE]) vs 8.5 months (95% CI, 5.9-NE) in the respective groups. In those treated with 160 to 300 mg of daraxonrasib, it was 8.5 months (95% CI, 5.3-11.7) vs 7.6 months (95% CI, 5.9-11.1).

An overall survival (OS) benefit was also observed among those identified with KRAS G12X mutations vs RAS mutations. For those treated with 300 mg of daraxonrasib, median OS was NE (95% CI, NE-NE) vs NE (95% CI, 8.5-NE) with 6-month OS rates of 100% and 97% (95% CI, 79%-100%), respectively. In patients treated with 160 to 300 mg of daraxonrasib, the median OS was 14.5 months (95% CI, 8.8-NE) and 14.5 months (95% CI, 8.8-NE), with 6-month OS rates of 89% (95% CI, 70%-97%) and 91% (95% CI, 71%-96%), respectively.

Transcript:

It is too early [to answer] that. This is a phase 1 trial, and that means that we need [further research] to understand this better. For instance, something we have not done in the data that we have presented is trying to understand if patients who have stable disease have a [better] response based on ctDNA. Do patients with stable disease that do not have a molecular response or decrease in the ctDNA [have longer PFS]?

What we can tell from the data is nearly everyone had some decrease in ctDNA. Over 90% of patients had some molecular response, some decreasing in ctDNA. [Approximately] 50% of patients had complete eradication of ctDNA. That is interesting and promising. How that translates to improved outcomes for patients with a stable disease is something we will need to understand with future follow-up.

Reference

Garrido-Laguna I, Wolpin B, Park W, et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025;43(suppl 4):722. doi:10.1200/JCO.2025.43.4_suppl.722

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content